Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035334 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
A Phase 2 study, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00035334 is a Phase 2 study that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 150 participants.
The verdict
NCT00035334, a Phase 2 study, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.
Interventions
- DRUG NC-503 (Anti-amyloidotic (AA) Agent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2001-10 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035334
The ClinicalTrials.gov registry entry for NCT00035334 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellus Health Inc. - a GSK company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NC-503 (Anti-amyloidotic (AA) Agent) is the first listed.
NCT00035334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035334 about?
NCT00035334 is a clinical study titled "Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis". The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.
What is the current status of trial NCT00035334?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2001-10. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00035334?
The interventions under investigation include: NC-503 (Anti-amyloidotic (AA) Agent) (DRUG).
Who is sponsoring clinical trial NCT00035334?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.